Quadrivalent Human Papilloma Virus (HPV) vaccine (GARDASILTM) is now available through the Washington State VFC Program for use among females aged 9 to18 years for prevention of vaccine HPV-type-related cervical cancer, cervical cancer precursors, vaginal and vulvar cancer precursors, and anogenital warts. The vaccine represents an important medical breakthrough and we encourage health care providers to recommend the HPV vaccine for all female patients who are eligible.
Approximately 70% of cervical cancers worldwide are caused by types 16 and 18 and approximately 90% of all anogenital warts (condyloma) are caused by HPV types 6 and 11. During 2007, an estimated 11,100 new cases of cervical cancer will be diagnosed in the US, and approximately 3,700 women will die from cervical cancer. An average of 57 King County women were diagnosed with cervical cancer annually between 1998 and 2002, and an average of 15 King County women died from cervical cancer annually between 1999 and 2003.
Here is a list of selected references and resources on HPV disease and HPV vaccine for clinicians, patients and parents. Immunization Program staff reviewed a large number of available resources and selected this core list of high quality information from authoritative sources that is clearly presented and covers key content areas. The hope is that these key resources are useful in increasing providers' knowledge about HPV vaccine and related issues, and in helping providers communicate with patients and parents about HPV disease and the importance of vaccination.Toolkit downloads (PDF):